Replies to post #53911 on RespireRx Pharmaceuticals Inc (fka RSPI)

[loanranger]

The fact that the CFO is providing you info for public distribution suddenly makes a lot of sense.
"I still think if BP buys it all it is around 2.5-3B".
Remarkable.

[LTListener]

I doubt that honestly.

These guys have continually stated to license, partner or sale all of their assets. And given the ampakine program history failures and no resources/expertise for clinicals and how this whole EM/presentation fiasco has been managed, BP surely would be looking to do a typical upfront payment with milestones and take control of development...

Now maybe the gabakine program goes into a newco and brand new management is brought in to run it, but I think by then all parties will want considerations for phantom, preferred, warrant and common shareholders all taken care of to go forward unencumbered. Dual paths of pain and epilepsy provides flexibility, but delays and fiddling around on the OTC will only cost significant longer term value of the asset. And of course competitors wont just stay idle either.

[LTListener]

A thought occurred to me...

Does the NIH HEAL program also sponsor and conduct the phase 1 safety trials in humans? I assumed IND enabling would be completed and then BP take over, but does the HEAL program directly fund/lead the initial phase 1 testing and then turn over the program to BP in phase 2 ?

Your 2.5 B seems far fetched, but maybe not so. Acadia and Saniona deal was for up to 580 million in milestones. And I think there are plenty of reasons to believe that KRM-ll-81 is far superior and applicable to both pain and epilepsy indications which are larger markets. Considering the markets, it is certainly plausible. Maybe I need to stretch my imagination a bit here... .50+ ??